We’re less than a week away from our biggest life sciences event of the year in the San Francisco Bay Area. So today it’s time to scratch an important event prep item off my to-do list, by giving you the updated agenda for our big conference on “Reinventing Biotech’s Business Model.”
This event will be held the afternoon of Oct. 16 at Onyx Pharmaceuticals’ headquarters in South San Francisco. The basic theme is that biotech has come under increasing pressure from investors to stop the overpromising, and start delivering more innovative new drugs. We’ve gathered a terrific crew of thinkers and doers who come at this problem from different angles—CEOs of publicly traded biotech companies, venture capitalists, startup executives, and Big Pharma innovation scouts.
There have been a couple of small changes to the agenda in the last week, but nothing major. Here’s how you can expect the afternoon to flow:
1 pm. Registration and networking.
2 pm. Welcoming remarks, Onyx Pharmaceuticals CEO Tony Coles & Xconomy’s Luke Timmerman.
2:10 pm. Opening keynote chat. I’m going to moderate a discussion featuring three biotech CEOs at publicly-traded companies who are under the gun to create more innovative products on tight R&D budgets.
—Tony Coles, CEO, Onyx Pharmaceuticals (NASDAQ: ONXX)
—Mike Morrissey, CEO, Exelixis (NASDAQ: EXEL)
—Robert Blum, CEO, Cytokinetics (NASDAQ: CYTK)
2:40 pm. Experiments with new biotech business models. I’m going to ask these speakers to share their adventures in seeking support for startups. These speakers won’t have to vie for attention on some mega-panel, but they will come up front one by one to tell their stories in 20-minute chunks.
—James Sabry, VP of partnering at Genentech, & Mark Goldsmith, venture partner at Third Rock Ventures. These two will be able to talk about how they worked together to support epigenetics R&D at Cambridge, MA-based Constellation Pharmaceuticals.
—Peter Thompson, a West Coast-based venture partner with OrbiMed Advisors, will be able to talk about why this big, diversified fund is concentrating on early-stage investments like Cambridge, MA-based Arteaus Therapeutics.
—Steve Kaldor, CEO of San Francisco-based Quanticel Pharmaceuticals, on Versant Ventures’ unusual partnership to advance this startup’s R&D program with Celgene (NASDAQ: CELG).
—Clare Ozawa, co-founder and chief business officer of Inception Sciences, and Brian Atwood, managing director of Versant Ventures, on creating an incubator that wants to spin out drug assets for Big Pharma to buy—not whole companies.
4 pm. Networking Break.
4:30 pm. In the late afternoon session, we’ll hear from speakers at Big Pharma companies who are charged with rethinking their relationships with innovators in academia and biotech. Each of these individual chats will go about 20 minutes.
—Jens Eckstein, president of GlaxoSmithKline’s SR One venture arm, on how “strategic” corporate venture groups have sought to fill the void during the decline of traditional VC.
—Diego Miralles, head of the Janssen Labs in San Diego, on the various experiments J&J is running to support innovations that it—or its competitors—may want to someday acquire.
—Richard Lindberg, executive director and head of the Centers for Therapeutic Innovation in California for Pfizer. Lindberg will be able to talk about the giant drugmaker’s partnership with UCSF, and what the company hopes will come from it.
5:30 pm. We will seek to put the afternoon’s stories in perspective, and hear some new ideas, from a trio of top biotech VCs. This closing keynote chat will go for about 30 minutes.
—Risa Stack, partner, Kleiner Perkins Caufield & Byers
—Deepa Pakianathan, general partner, Delphi Ventures
6 pm. Networking reception
I’ll have plenty of questions ready for all these speakers, but I also will be sure to ask for questions from those of you in the audience. Space is limited, so be sure to get your tickets in advance. Most of all, be ready to come away with a few new connections and new ideas about this big challenge for the biotech industry. See you there Oct. 16.